Skip to main content
OpenTrials
Completed

NCT Number: NCT06593847

Multisite Virtual Reality Intervention for Speech Anxiety

Exposure-based cognitive behavior therapy is an efficacious treatment for speech anxiety and has been delivered effectively in a virtual reality (VR) environment. The present multicenter study (conducted through the Exposure Therapy Consortium) is designed to evaluate whether trait versus state positive affectivity is a more effective predictor of exposure therapy outcomes. Further, the investigators will examine whether the predictive significance of trait positive affectivity can be accounted for by examination of baseline levels of self-efficacy, hope, and optimism.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–70 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Western Sydney University, Penrith, New South Wales, Australia

Loading trial locations.

About this study

The goal of this multicenter clinical trial is to examine predictors of VR exposure therapy outcomes for college students with public speaking anxiety following a positive or negative mood induction. The overarching aim of the present study is to evaluate whether trait versus state positive affectivity is a more effective predictor of exposure therapy outcomes. Further, the investigators will examine whether the predictive significance of trait positive affectivity can be accounted for by examination of baseline levels of self-efficacy, hope, and optimism. State affect is manipulated at an experimental level with affect induction procedures; trait positive affectivity is measured at baseline.

The study involves three phases: (1) initial screening, (2) in-person assessment and brief exposure intervention for a subset of participants with elevated public speaking anxiety, and (3) a one-week follow-up assessment conducted online. Students who choose to participate and screen high on a public speaking anxiety scale will be assigned to a positive or negative mood induction condition prior to undergoing VR-based exposure therapy. Public speaking and social anxiety outcomes are measured immediately post-intervention and one week later. The one-week follow-up assessment represents the primary outcome.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Self-report of 18 - 70 years of age
  • Current student at a participating University
  • Ability to read English to provide informed consent
  • Familiarity with a computer keyboard and mouse or a touch screen device (e.g. phone, tablet).
  • For Phase 2: speech anxiety scale score of ≥ 18 on the Personal Report of Communication Apprehension, Public Speaking Subscale (PRCA-PS)

Exclusion criteria

  • Previous participation (i.e., no participant may take the survey more than once).

Treatment and study plan

Single-session VR exposure intervention

Behavioral

VR exposure is the only intervention, but the VR intervention is conducted following either positive or negative mood induction.

Primary outcomes

  1. Public Speaking Anxiety

    Time frame: One week follow-up assessment

    Assessed using the Personal Report of Communication Apprehension, Public Speaking Subscale (PRCA-PS). Scores range from 6 to 30, with higher scores associated with higher public speaking anxiety.

Secondary outcomes

  1. Valence

    Time frame: One week follow-up assessment

    Self-report measure of how participant feels about having to give a speech

  2. Assessed using the Social Phobia Inventory (SPIN)

    Time frame: One week follow-up assessment

    Assessed using the Social Phobia Inventory (SPIN). Scores range from 0-68, with higher scores indicating greater social phobia.

  3. Public Speaking Anxiety

    Time frame: Post-treatment assessment immediately after the intervention

    Assessed using the Personal Report of Communication Apprehension, Public Speaking Subscale (PRCA-PS). Scores range from 6 to 30, with higher scores associated with higher public speaking anxiety.

Sponsors and collaborators

Lead sponsor

Boston University Charles River Campus

Other

Collaborators

  • Albright College
  • Curtin University
  • Erasmus University Rotterdam
  • National University of Singapore
  • Philipps Universität Marburg
  • Southern Illinois University
  • The University of Hong Kong
  • The University of New South Wales
  • Tufts University
  • University of Arizona
  • University of Texas at Austin
  • University of Western Sydney
  • Utrecht University

Registry information

Acronym: ETC2

Important dates

Study start
2024
Primary completion
2025
Study completion
2025
First posted
Sep 19, 2024
Registry last updated
Dec 18, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.